Before revision: Regulatory harmonization In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and EMA agreed in late 2007 to utilize a common application process for both agencies.
After revision: Regulatory harmonization In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and European Medicines Agency (EMA) agreed in late 2007 to utilize a common application process for both agencies.